Recursion reports positive Phase 1/2 data for REC-1245, Phase 2 proof-of-concept for REC-4881

Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read

Key Changes

• high

  REC-1245 well-tolerated in 16 patients with no dose-limiting toxicities; showed predictable exposure and target engagement, with dose escalation ongoing to determine Phase 2 dose.

  Exhibit 99.1 verify on EDGAR →
• high

  REC-4881 achieved 43% median polyp reduction at Week 13 (deepening to 53% at Week 25) in FAP patients; company initiated FDA engagement for registrational study design with update expected in second half of 2026.

  Exhibit 99.1 verify on EDGAR →
• high

  Q1 2026 cash position of $665.2 million with operating cash burn of $81.1 million (down from $132.0 million in Q1 2025); company reiterates runway into early 2028 without additional financing.

  Exhibit 99.1 verify on EDGAR →